Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease
| Autor: | Armin Steinmetz, Michel Farnier, Kjetil Retterstøl, Albert Császár |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
Simvastatin medicine.medical_specialty Combination therapy Endocrinology Diabetes and Metabolism Hyperlipidemias Pharmacology Gastroenterology chemistry.chemical_compound Pharmacotherapy Double-Blind Method Fenofibrate Ezetimibe Internal medicine Internal Medicine Humans Medicine Aged Hypolipidemic Agents Pravastatin medicine.diagnostic_test business.industry Cholesterol Cholesterol HDL Cholesterol LDL Middle Aged Drug Combinations Treatment Outcome Diabetes Mellitus Type 2 chemistry Cardiovascular Diseases Azetidines Drug Therapy Combination Female lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine business Lipid profile medicine.drug |
| Zdroj: | Diabetes and Vascular Disease Research. 9:205-215 |
| ISSN: | 1752-8984 1479-1641 |
| DOI: | 10.1177/1479164111430715 |
| Popis: | Background: This study was designed to compare the efficacy and safety of a fenofibrate/pravastatin 160/40 mg fixed-dose combination plus ezetimibe 10 mg triple therapy and simvastatin 20 mg plus ezetimibe 10 mg dual therapy in patients with type 2 diabetes, mixed hyperlipidaemia and cardiovascular disease. Method: After a 6-week run-in period on simvastatin 20 mg, 273 patients with non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dl or low-density lipoprotein cholesterol (LDL-C) ≥ 70 mg/dl were randomised to receive 12-week treatment with triple therapy or dual therapy, followed by a 12-week safety period during which all patients received the triple therapy. Results: At week 12, similar significant decreases in non-HDL-C were observed with both treatments. The triple therapy has induced a greater decrease in triglycerides (between-treatment difference: −14.6%, p = 0.007) and the dual therapy a greater decrease in LDL-C (between-treatment difference: +5.3%, p = 0.05). Both treatments were generally well tolerated. Conclusion: The fenofibrate/pravastatin plus ezetimibe therapy improves the global atherogenic lipid profile in type 2 diabetic patients with mixed hyperlipidaemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|